文献速递妇科肿瘤

阿替利珠单抗联合化疗治疗晚期或复发性子宫内膜癌(AtTEnd):一项随机、双盲、安慰剂对照的3期试验

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2024-08-02

AtTEnd是一项在11个国家89家医院开展的多中心、双盲、随机、安慰剂对照3期试验,评估阿替利珠单抗联合卡铂和紫杉醇化疗用于晚期或复发性子宫内膜癌的疗效。共551例患者随机(2:1)接受阿替利珠单抗(n=362)或安慰剂(n=189)联合化疗。错配修复缺陷(dMMR)人群中,阿替利珠单抗组中位无进展生存期不可估计(95%CI 12.4个月-不可估计),安慰剂组为6.9个月(95%CI 6.3-10.1)(HR 0.36,95%CI 0.23-0.57;p=0.0005)。

要点

  • dMMR人群阿替利珠单抗组中位PFS不可估计 vs 安慰剂组6.9个月(HR 0.36,95%CI 0.23-0.57;p=0.0005)。
  • 总体人群中位PFS阿替利珠单抗组10.1个月 vs 安慰剂组8.9个月(HR 0.74,95%CI 0.61-0.91;p=0.022)。
  • 中位总生存阿替利珠单抗组38.7个月 vs 安慰剂组30.2个月(HR 0.82,95%CI 0.63-1.07;log-rank p=0.048),未跨过停止边界。

核心结论

  • 阿替利珠单抗联合化疗增加了晚期或复发性子宫内膜癌患者的无进展生存期,尤其在dMMR癌中,提示在该特定亚组一线标准化疗中加入阿替利珠单抗。

研究设计与样本

  • AtTEnd为多中心、双盲、随机、安慰剂对照3期试验,在11个国家89家医院开展。
  • 纳入≥18岁、晚期或复发性子宫内膜癌或癌肉瘤、ECOG体能状态0-2、复发后未接受过全身化疗的患者。
  • 按2:1随机分配至阿替利珠单抗1200 mg或安慰剂静脉给药联合化疗(卡铂AUC 5或6,紫杉醇175 mg/m2,第1天,每21天),6-8周期后继续至疾病进展。
  • 分层因素为国家、组织学亚型、晚期或复发状态、MMR状态;主要分析在意向治疗人群中进行。
  • 2018年10月3日至2022年1月7日共551例患者随机:阿替利珠单抗组362例,安慰剂组189例;阿替利珠单抗组2例因缺乏同意被排除所有分析。

主要发现

  • 中位随访28.3个月(IQR 21.2-37.6);阿替利珠单抗组81例(23%)、安慰剂组44例(23%)经中心评估为dMMR。
  • dMMR人群中位PFS:阿替利珠单抗组不可估计(95%CI 12.4个月-不可估计)vs 安慰剂组6.9个月(95%CI 6.3-10.1)(HR 0.36,95%CI 0.23-0.57;p=0.0005)。
  • 总体人群中位PFS:阿替利珠单抗组10.1个月(95%CI 9.5-12.3)vs 安慰剂组8.9个月(95%CI 8.1-9.6)(HR 0.74,95%CI 0.61-0.91;p=0.022)。
  • 中位OS:阿替利珠单抗组38.7个月(95%CI 30.6-不可估计)vs 安慰剂组30.2个月(95%CI 25.0-37.2)(HR 0.82,95%CI 0.63-1.07;log-rank p=0.048); interim OS分析p值未跨过停止边界,试验将继续至所需事件数。
  • 最常见3-4级不良事件:中性粒细胞减少(阿替利珠单抗组97/356例[27%] vs 安慰剂组51/185例[28%])和贫血(49例[14%] vs 24例[13%])。

临床怎么用

  • 作者认为,在晚期或复发性子宫内膜癌患者中,尤其是dMMR癌患者,阿替利珠单抗联合化疗增加了无进展生存期,提示在该特定亚组一线标准化疗中加入阿替利珠单抗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: At the time of AtTEnd trial design, standard treatment for advanced or recurrent endometrial cancer included carboplatin and paclitaxel chemotherapy. This trial assessed whether combining atezolizumab with chemotherapy might improve outcomes in this population. METHODS: AtTEnd was a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial done in 89 hospitals in 11 countries across Europe, Australia, New Zealand, and Asia. Enrolled patients were aged 18 years or older, and had advanced or recurrent endometrial carcinoma or carcinosarcoma, an Eastern Cooperative Oncology Group performance status of 0-2, and received no previous systemic chemotherapy for recurrence. Patients were randomly assigned (2:1) using an interactive web response system (block size of six) to either atezolizumab 1200 mg or placebo given intravenously with chemotherapy (carboplatin at area under the curve of 5 or 6 and paclitaxel 175 mg/m2 intravenously on day 1 every 21 days) for 6-8 cycles, then continued until progression. Stratification factors were country, histological subtype, advanced or recurrent status, and mismatch repair (MMR) status. Participants and treating clinicians were masked to group allocation. The hierarchically tested co-primary endpoints were progression-free survival (in patients with MMR-deficient [dMMR] tumours, and in the overall population) and overall survival (in the overall population). Primary analyses were done in the intention-to-treat population, defined as all randomly assigned patients who gave their full consent to participation in the study and data processing. Safety was assessed in all patients included in the intention-to-treat population who received at least one dose of study treatment. Here, we report the primary progression-free survival and the interim overall survival results. This study is ongoing and is registered with ClinicalTrials.gov, NCT03603184. FINDINGS: Between Oct 3, 2018, and Jan 7, 2022, 551 patients were randomly assigned to atezolizumab (n=362) or placebo (n=189). Two patients in the atezolizumab group were excluded from all analyses due to lack of consent. Median follow-up was 28·3 months (IQR 21·2-37·6). 81 (23%) patients in the atezolizumab group and 44 (23%) patients in the placebo group had dMMR disease by central assessment. In the dMMR population, median progression-free survival was not estimable (95% CI 12·4 months-not estimable [NE]) in the atezolizumab group and 6·9 months (6·3-10·1) in the placebo group (hazard ratio [HR] 0·36, 95% CI 0·23-0·57; p=0·0005). In the overall population, median progression-free survival was 10·1 months (95% CI 9·5-12·3) in the atezolizumab group and 8·9 months (8·1-9·6) in the placebo group (HR 0·74, 95% CI 0·61-0·91; p=0·022). Median overall survival was 38·7 months (95% CI 30·6-NE) in the atezolizumab group and 30·2 months (25·0-37·2) in the placebo group (HR 0·82, 95% CI 0·63-1·07; log-rank p=0·048). The p value for the interim analysis of overall survival did not cross the stopping boundary; therefore, the trial will continue until the required number of events are recorded. The most common grade 3-4 adverse events were neutropenia (97 [27%] of 356 patients in the atezolizumab group vs 51 [28%] of 185 in the placebo group) and anaemia (49 [14%] vs 24 [13%]). Treatment-related serious adverse events occurred in 46 (13%) patients in the atezolizumab group and six (3%) patients in the placebo group. Treatment-related deaths occurred in two patients (pneumonia in one patient in each group). INTERPRETATION: Atezolizumab plus chemotherapy increased progression-free survival in patients with advanced or recurrent endometrial carcinoma, particularly in those with dMMR carcinomas, suggesting the addition of atezolizumab to standard chemotherapy as first-line treatment in this specific subgroup. FUNDING: F Hoffmann-La Roche.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Colombo N, Biagioli E, Harano K, et al. Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2024. PMID: 39102832. doi:10.1016/S1470-2045(24)00334-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。